MedTrace Logo

Pharmacokinetic Study for PCA Derivate Formulations

NCT00729729 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-08-28

No results posted yet for this study

Summary

A comparative bioavailability study of PCA slow release versus immediate release formulations, after a single dose to fasting healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

PCA

Placebo tablet, once

DRUG

PCA

PO, 700mg, once

DRUG

PCA

PO, 1000mg, once

Sponsors & Collaborators

  • Hadassah Medical Organization

    lead OTHER

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-02-28
Completion
2009-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00729729 on ClinicalTrials.gov